Don't refer minor cases to Rims: Health min
Tired of too many ads? go ad free now
Ansari, who reviewed the department's works at the IPH auditorium in Namkum, asked civil surgeons to ensure that Sadar hospitals across the districts must provide appropriate treatments at their level. "Stop referring patients with minor ailments to Rims. Providing better treatment to the patient is the first responsibility at district hospitals," Ansari said.
The move, officials said, is aimed at reducing patient load in the state's largest govt run medical college and hospital in the state capital.
During the review, Ansari made it clear that excuses like lack of doctors, medicines, or ambulances will no longer be acceptable. He directed all civil surgeons to ensure that patients receive timely and quality healthcare within district facilities. Stressing accountability, he issued a stern warning regarding ambulance services. "If death occurs due to negligence of ambulance, the civil surgeon will be held responsible," he said.
Several announcements were made in the meeting to modernise and strengthen district-level healthcare. From August 15, free Wi-Fi will be operational in sadar hospitals, while specialist OPD services involving doctors from major cities like Ranchi, Patna, Kolkata, and Delhi will also be introduced. Furthermore, a digital push was announced under the Chief Minister's Digital Health Mission, with deadlines to connect high-speed internet lease lines and Wi-Fi across healthcare facilities by September 15 for sub-divisional hospitals, October 15 for Sadar and community health centres and November 15 for primary health centres.
Other directives included empanelling all govt hospitals under the Ayushman Bharat Yojana and setting a revenue target of Rs 6 crore annually for each district hospital.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
2 hours ago
- Time of India
Body of Kodagu man being brought back from Guyana
Madikeri: Mortal remains of a resident of Kodagu, who died in Guyana, will be brought back to India, the Non-Resident Indian Forum said on Wednesday. The state govt will extend financial assistance to bring back the body of PB Girish Babu Pale, who is a native of Madenadu village in Madikeri taluk, it stated. Girish was working as a staff nurse in the Sheriff General Hospital in Guyana, South America, for about two years. On July 3, he was admitted to the hospital where he was working due to illness and was undergoing treatment. However, he died of a heart attack on July 14. Following the incident, the family was in constant touch with the hospital and the Indian Embassy to bring the mortal remains to India. The embassy informed that the family of the deceased would have to pay about Rs 12 lakhs to bring the mortal remains to India. Janaki, wife of Girish, appealed to the Non-Resident Indian Forum for assistance from the govt, stating that the family was financially backward. Accordingly, the forum requested chief minister Siddaramaiah to consider the request. Janaki also met the CM and sought his intervention. In response, the state govt sanctioned Rs 3.6 lakh while the remaining amount is being borne by the Sheriff General Hospital where Girish worked, the Forum stated on Wednesday. In addition, the alumni of Basavanahalli Morarji Desai Residential School, where Girish studied, approached Virajpet MLA AS Ponnanna and requested him to provide financial assistance. The Indian Embassy in Guyana and the resident commissioner in New Delhi are coordinating the bringing of the body to India.
Economic Times
3 hours ago
- Economic Times
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
Dr. Reddy's Laboratories is closely monitoring a potential US tariff on the pharma sector, viewing it as both a risk and opportunity. The company plans a significant expansion with the generic version of semaglutide across 87 countries by 2026, alongside developing 26 GLP-1 products over the next decade. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET.'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.'The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver.'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query.'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade.'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio company's India and emerging markets business grew 11% and 17% company's EBITDA margin for the first quarter stood at 26.7%.
Time of India
3 hours ago
- Time of India
Potential US tariff a significant 'unknown' for business, says Dr Reddy's Lab CEO
A potential US tariff on the pharma sector is a significant 'unknown' and will be one of the key developments for Dr Reddy's Laboratories to watch over the next few quarters, its chief executive officer, Erez Israeli , told ET. 'Don't know whether to call it a risk, but it is an unknown that could develop into a risk, and that is the tariff. We will know better as time will come about what it means and what we can do,' Israeli said over an earning call on Wednesday. 'It's not necessarily bad, it can also create an opportunity. It very much depends on what will be our relative situation to Chinese players or others.' Explore courses from Top Institutes in Please select course: Select a Course Category Technology Leadership Project Management Healthcare Management Data Analytics Data Science others Cybersecurity Artificial Intelligence Design Thinking Degree Product Management Public Policy Data Science MCA Finance MBA Others healthcare Operations Management PGDM CXO Digital Marketing Skills you'll gain: Duration: 12 Weeks MIT xPRO CERT-MIT XPRO Building AI Prod India Starts on undefined Get Details The Hyderabad-based drug maker, which announced its first-quarter earnings, is betting big on generic version of Novo Nordisk 's weight loss molecule semaglutide – that it plans to launch in 87 countries in 2026 - as a future growth driver. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo 'Our levers for the future consist of double-digit growth of the main business and then on top of it the success of semaglutide, which is very important to us, business development and our ability to optimise our resources,' Israeli said in response to ET's query. 'We are planning to launch semaglutide in 87 countries as the patent in the relevant country will allow us… We have some countries where there is no active patent as we speak, and in those we can launch. In the other countries, we need to wait for the patent expiration - for example Brazil or India - in which the patent goes on till March 2026. We are absolutely ready to launch on day 1 (post patent expiry) in each one of these markets,' he said. Live Events The company which is among the frontrunners for GLP-1 drugs is looking at launching 26 other products in the space over the next decade. 'We have 26 products (all peptides) in the GLP1 pipeline and will be launched over the next decade, according to the patent situation,' said Israeli. On Wednesday, the company reported consolidated revenue for the first quarter at Rs 8,545 crore, an 11% increase from a year ago, mainly on account of contributions from its acquired consumer healthcare portfolio in nicotine replacement therapy (NRT) and sustained performance in branded markets. Net profit for the quarter stood at Rs 1,418 crore, up 2% y-o-y. Israeli said an ongoing litigation over semaglutide with innovator company Novo Nordisk in India is not likely to hamper its planned product launches. The company's global generics revenue in Q1FY26 stood at Rs 7,562 crore, a growth of 10% year-on-year. However, revenue from North America–one of its key markets–declined 11% y-o-y to Rs 3,412 crore due to increased price erosion in select products, including lenalidomide. Its Europe revenue stood at Rs 1,274 crore, up 142% on account of NRT portfolio acquisition. The company's India and emerging markets business grew 11% and 17% respectively. The company's EBITDA margin for the first quarter stood at 26.7%.
